Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 4 | History Defined

AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules

AbbVie Inc. (NYSE:ABBV), the manufacturer of Imbruvica, is at the center of a constitutional challenge to the federal government's new Drug Price Negotiation Program.

Benzinga

AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?

Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Dividend Stocks With Solid Returns And More Growth Ahead

Sector by sector, U.S. dividend stocks have outperformed so far this year, with historically dividend-friendly industries surpassing those with a more growth-oriented focus.

Benzinga

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

MarketBeat

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

Benzinga

Seven all-American products that are actually 'Made in Europe', set to be hit by US tariffs

Trump’s tariffs are aimed at ostensibly boosting US production and fostering a “local for locals” sensibility. Except, it turns out that several American product staples are actually... "Made in Europe"?

Euronews

Read news from The Economist, FT, and more,
with one subscription

Uber, Western Union, Live Nation Entertainment And A Health Care Stock On CNBC's 'Final Trades'

As investors navigate a volatile market landscape, attention turns to upcoming earnings reports from major companies, which could provide insights into broader economic trends. This earnings season, analysts and investors are closely watching key players like AbbVie, Uber, and Western Union for signs of growth and stability amid shifting market…

Benzinga

Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades'

The investment landscape is shifting as companies across various sectors demonstrate resilience and innovation, prompting investors to reassess their portfolios.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Benzinga

Here's What to Expect From AbbVie's Next Earnings Report

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Barchart

3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now

These dividend stocks provide consistent income and long-term stability.

Barchart

3 Dividend Growth Stocks To Buy and Hold Forever

These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.

Barchart

How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks?

AbbVie has outperformed the Pharmaceuticals industry over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

Barchart

Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?

AbbVie has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

MarketBeat

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

Marie Claire

Tariffs Are About to Make Your Beauty Routine a Lot More Expensive

Here are the treatments that are most vulnerable to price hikes.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.

Barchart

Earnings Preview: What to Expect From AbbVie's Report

AbbVie is scheduled to report its first-quarter results this month, with analysts anticipating a modest growth in earnings.

MarketBeat

3 Biopharmaceutical Stocks Bucking the Sell-Off

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

Euronews

Did pharma sector dodge Trump’s tariffs? The EU's not so sure

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

MarketBeat

AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

Barchart

3 Top Dividend Kings to Scoop Up for Passive Income

Dividend Kings are good choices for reliable, low-risk investing.

MarketBeat

These Stocks Missed on Earnings, But Will Rebound Next Quarter

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.